Barbara A. Forey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Barbara A. Forey has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Peter Nicholas Lee
P.N. Lee Statistics and Computing Ltd., Sutton, UK
6 shared publications - Alison J. Thornton
Independent Consultant, Oak Cottage, Beer Farm, Okehampton, Devon, EX20 1SG, UK
2 shared publications - John S. Fry
RoeLee Statistics Ltd, Sutton, Surrey, SM2 5DA, UK
2 shared publications - Katharine J Coombs
P.N. Lee Statistics and Computing Ltd, Surrey, UK
2 shared publications - Katharine J. Coombs
P N Lee Statistics and Computing Ltd, Sutton, Surrey, United Kingdom
2 shared publications - Peter J. Lipowicz
Research, Development & Regulatory Affairs, Altria Client Services LLC , 601 East Jackson Street, Richmond, Virginia 23219, United States
1 shared publication
Latest Publications
- Open Access
- 1 February 2016
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 74, 12-22
Time trends in never smokers in the relative frequency of the different histological types of lung cancer, in particular adenocarcinoma
- 1 February 2016
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 74, 12-22
Open AccessTime trends in never smokers in the relative frequency of the different histological types of lung cancer, in particular adenocarcinoma
- Open Access
- 1 June 2015
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 72 (1) , 49-57
Is the shape of the decline in risk following quitting smoking similar for squamous cell carcinoma and adenocarcinoma of the lung? A quantitative review using the negative exponential model
- 1 June 2015
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 72 (1) , 49-57
Open AccessIs the shape of the decline in risk following quitting smoking similar for squamous cell carcinoma and adenocarcinoma of the lung? A quantitative review using the negative exponential model
- Open Access
- 13 September 2013
- Published by Springer Nature in Biomarker Research
- Vol. 1 (1) , 26
The effect of quitting smoking on HDL-cholesterol - a review based on within-subject changes
A higher concentration of high density lipoprotein cholesterol (HDL-C) in ex-smokers than smokers has consistently been observed. Better evidence of quitting effects comes from within-subject changes. We extend an earlier meta-analysis to quantify the reduction, and investigate variation by time quit and other factors. We conducted Medline and Cochrane searches for studies measuring HDL-C in subjects while still smoking and later having quit. Using unweighted and inverse-variance weighted regression analysis, we related changes (in mmol/l) to intra-measurement period, and estimated time quit, and to study type, location and start year, age, sex, product smoked, validation of quitting, baseline HDL-C, baseline and change in weight/BMI, and any study constraints on diet or exercise. Forty-five studies were identified (17 Europe, 16 North America, 11 Asia, 1 Australia). Thirteen were observational, giving changes over at least 12 months, with most involving >1000 subjects. Others were smoking cessation trials, 12 randomized and 20 non-randomized. These were often small (18 of <100 subjects) and short (14 of <10 weeks, the longest a year). Thirty studies provided results for only one time interval. From 94 estimates of HDL-C change, the unweighted mean was 0.107 (95% CI 0.085-0.128). The weighted mean 0.060 (0.044 to 0.075) was lower, due to smaller estimates in longer term studies. Weighted means varied by time quit (0.083, 0.112, 0.111, 0.072, 0.058 and 0.040 for <3, 3 to <6, 6 to <13, 13 to <27, 27 to <52 and 52+ weeks, p=0.006). After adjustment for time quit, estimates varied by study constraint on diet/exercise (p=0.003), being higher in studies requiring subjects to maintain their pre-quitting habits, but no other clear differences were seen, with significant (p<0.05) increases following quitting being evident in all subgroups studied, except where data were very limited. For both continuing and never smokers, the data are (except for two large studies atypically showing significant HDL-C declines in both groups, and a smaller decline in quitters) consistent with no change, and contrast markedly with the data for quitters. We conclude that quitting smoking increases HDL-C, and that this increase occurs rapidly after quitting, with no clear pattern of change thereafter.
- 13 September 2013
- Published by Springer Nature in Biomarker Research
- Vol. 1 (1) , 26
Open AccessThe effect of quitting smoking on HDL-cholesterol - a review based on within-subject changes
A higher concentration of high density lipoprotein cholesterol (HDL-C) in ex-smokers than smokers has consistently been observed. Better evidence of quitting effects comes from within-subject changes. We extend an earlier meta-analysis to quantify the reduction, and investigate variation by time quit and other factors. We conducted Medline and Cochrane searches for studies measuring HDL-C in subjects while still smoking and later having quit. Using unweighted and inverse-variance weighted regression analysis, we related changes (in mmol/l) to intra-measurement period, and estimated time quit, and to study type, location and start year, age, sex, product smoked, validation of quitting, baseline HDL-C, baseline and change in weight/BMI, and any study constraints on diet or exercise. Forty-five studies were identified (17 Europe, 16 North America, 11 Asia, 1 Australia). Thirteen were observational, giving changes over at least 12 months, with most involving >1000 subjects. Others were smoking cessation trials, 12 randomized and 20 non-randomized. These were often small (18 of <100 subjects) and short (14 of <10 weeks, the longest a year). Thirty studies provided results for only one time interval. From 94 estimates of HDL-C change, the unweighted mean was 0.107 (95% CI 0.085-0.128). The weighted mean 0.060 (0.044 to 0.075) was lower, due to smaller estimates in longer term studies. Weighted means varied by time quit (0.083, 0.112, 0.111, 0.072, 0.058 and 0.040 for <3, 3 to <6, 6 to <13, 13 to <27, 27 to <52 and 52+ weeks, p=0.006). After adjustment for time quit, estimates varied by study constraint on diet/exercise (p=0.003), being higher in studies requiring subjects to maintain their pre-quitting habits, but no other clear differences were seen, with significant (p<0.05) increases following quitting being evident in all subgroups studied, except where data were very limited. For both continuing and never smokers, the data are (except for two large studies atypically showing significant HDL-C declines in both groups, and a smaller decline in quitters) consistent with no change, and contrast markedly with the data for quitters. We conclude that quitting smoking increases HDL-C, and that this increase occurs rapidly after quitting, with no clear pattern of change thereafter.
- Open Access
- 9 April 2013
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 189
Indirectly estimated absolute lung cancer mortality rates by smoking status and histological type based on a systematic review
National smoking-specific lung cancer mortality rates are unavailable, and studies presenting estimates are limited, particularly by histology. This hinders interpretation. We attempted to rectify this by deriving estimates indirectly, combining data from national rates and epidemiological studies.
- 9 April 2013
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 189
Open AccessIndirectly estimated absolute lung cancer mortality rates by smoking status and histological type based on a systematic review
National smoking-specific lung cancer mortality rates are unavailable, and studies presenting estimates are limited, particularly by histology. This hinders interpretation. We attempted to rectify this by deriving estimates indirectly, combining data from national rates and epidemiological studies.
- Open Access
- 3 September 2012
- Published by Springer Nature in BMC Cancer
- Vol. 12 (1) , 385
Systematic review with meta-analysis of the epidemiological evidence in the 1900s relating smoking to lung cancer
Smoking is a known lung cancer cause, but no detailed quantitative systematic review exists. We summarize evidence for various indices.
- 3 September 2012
- Published by Springer Nature in BMC Cancer
- Vol. 12 (1) , 385
Open AccessSystematic review with meta-analysis of the epidemiological evidence in the 1900s relating smoking to lung cancer
Smoking is a known lung cancer cause, but no detailed quantitative systematic review exists. We summarize evidence for various indices.
- Top Cited PapersOpen Access
- 14 June 2011
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 11 (1) , 36
Systematic review with meta-analysis of the epidemiological evidence relating smoking to COPD, chronic bronchitis and emphysema
Smoking is a known cause of the outcomes COPD, chronic bronchitis (CB) and emphysema, but no previous systematic review exists. We summarize evidence for various smoking indices.
- 14 June 2011
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 11 (1) , 36
Top Cited PapersOpen AccessSystematic review with meta-analysis of the epidemiological evidence relating smoking to COPD, chronic bronchitis and emphysema
Smoking is a known cause of the outcomes COPD, chronic bronchitis (CB) and emphysema, but no previous systematic review exists. We summarize evidence for various smoking indices.